Nature Reviews Drug Discovery 14, 642–662 (2015)
The following footnote has been added to Table 1: Although some adeno- and herpes viruses have the potential for nuclear integration, most oncolytic viruses under clinical development do not integrate into the nucleus.
Additional information
The online version of the original article can be found at 10.1038/nrd4663
Rights and permissions
About this article
Cite this article
Kaufman, H., Kohlhapp, F. & Zloza, A. Erratum: Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 15, 660 (2016). https://doi.org/10.1038/nrd.2016.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.178
This article is cited by
-
The artificial amino acid change in the sialic acid-binding domain of the hemagglutinin neuraminidase of newcastle disease virus increases its specificity to HCT 116 colorectal cancer cells and tumor suppression effect
Virology Journal (2024)
-
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial
Nature Medicine (2023)
-
Oncolytic Viruses and Cancer Immunotherapy
Current Oncology Reports (2023)
-
Novel classes of immunotherapy for breast cancer
Breast Cancer Research and Treatment (2022)
-
Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma
Cancer Immunology, Immunotherapy (2022)
